Datapoint: FDA Approves First Interchangeable Humira Biosimilar

The FDA last week approved Boehringer Ingelheim’s Cyltezo as the first interchangeable biosimilar for AbbVie’s Humira. It is the second U.S.-approved interchangeable biosimilar overall, behind Viatris and Biocon’s Semglee. Cyltezo was approved for a number of inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriatic arthritis. For the treatment of rheumatoid arthritis, Humira holds preferred status under the pharmacy benefit for 11.6% of all covered lives, growing to 63.5% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 10/25/21

0

0

0 Comments

0

0

• Datapoint